---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-314994"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2025-12-11T23:59:59+00:00"
generated_at: "2026-05-16T13:31:47.249201+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Immunovant prices $550M stock offering; updates IMVT-1402 and batoclimab timelines

## Summary
- Underwritten common stock offering of ~$550M gross proceeds; Roivant Sciences to purchase shares; expected close Dec 12, 2025.
- Potentially registrational D2T RA trial of IMVT-1402: top-line results now expected in 2026 (previously initial open-label only in 2026).
- Batoclimab Phase 3 TED studies: top-line results delayed to H1 2026 (previously by end of 2025); results shared concurrently.
- Discussions commenced with HanAll to potentially return batoclimab rights; may result in dispute or arbitration.
- Existing cash plus offering proceeds expected to fund operations through potential commercial launch of IMVT-1402 in Graves' Disease.

## SEC filing metadata
- accession: 0001193125-25-314994
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2025-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000119312525314994/0001193125-25-314994-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000119312525314994/d760155d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-314994
- JSON: https://secwatch.observer/filing/0001193125-25-314994.json
- Plain text: https://secwatch.observer/filing/0001193125-25-314994.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.